Cargando…

Use of Tadalafil for Treating Pulmonary Arterial Hypertension Secondary to Chronic Obstructive Pulmonary Disease

Pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD) is incurable and it has an unpredictable survival rate. Two men who suffered from COPD presented with progressive dyspnea and edema, respectively. PAH, as estimated by the peak velocity of tricuspidal reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyun-Sook, Park, Jae-Hyeong, Park, Seoung Ju, Park, Jong Kwan, Lee, Heung-Bum
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2007
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687595/ https://www.ncbi.nlm.nih.gov/pubmed/17427645 http://dx.doi.org/10.3904/kjim.2007.22.1.37

Ejemplares similares

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in Stable Asthma and Chronic Obstructive Pulmonary Disease
por: Park, Seoung-Ju, et al.
Publicado: (2005)

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension
por: Katz, Stuart D.
Publicado: (2007)

Systematic Review and Meta-Analysis of Pulmonary Hypertension Specific Therapy for Exercise Capacity in Chronic Obstructive Pulmonary Disease
por: Park, Jinkyeong, et al.
Publicado: (2013)

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
por: Falk, Jeremy A, et al.
Publicado: (2010)

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Henrie, Adam M, et al.
Publicado: (2015)

Pregnancy in Patients with Pulmonary Arterial Hypertension “To Deliver, or Not to Deliver: That Is the Question”
por: Park, Jae-Hyeong
Publicado: (2019)

Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
por: Maron, Bradley A., et al.
Publicado: (2022)

Long-term improvement during tadalafil therapy in a patient with pulmonary hypertension secondary to pulmonary Langerhans cell histiocytosis
por: Nemoto, Kenji, et al.
Publicado: (2016)

A Case of Acute Pulmonary Thromboembolism after Taking Tadalafil
por: Lee, Jinwoo, et al.
Publicado: (2012)

Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization
por: Elbardisy, Bassant, et al.
Publicado: (2022)

Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model
por: Ferguson-Sells, Lisa, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension
por: Rehmel, Jessica, et al.
Publicado: (2021)

Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
por: Park, Yong Kyu, et al.
Publicado: (2011)

Plasma Cell Granuloma Associated with Pulmonary Actinomycosis: A Case Report
por: Park, Seoung-Ju, et al.
Publicado: (2006)

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study
por: Small, David, et al.
Publicado: (2019)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension
por: Chung, Wook-Jin, et al.
Publicado: (2015)

Pulmonary hypertension due to obstructive sleep apnea in a child with Rubinstein-Taybi syndrome
por: Choi, Hyung Soon, et al.
Publicado: (2012)

Utility of D-shaped Left Ventricle and Mitral E/E′ in Patients with Pulmonary Hypertension
por: Park, Jae-Hyeong
Publicado: (2018)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2017)

Exercise-induced desaturation during a six-minute walk test is associated with poor clinical outcomes in patients with pulmonary arterial hypertension
por: Choi, Jung Hyun, et al.
Publicado: (2023)

Clinical Characteristics of Chronic Obstructive Pulmonary Disease in Female Patients: Findings from a KOCOSS Cohort
por: Choi, Joon Young, et al.
Publicado: (2020)

Pulmonary Artery Obstruction Caused by Leiomyosarcoma
por: Kang, Dong Seon, et al.
Publicado: (2020)

Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease
por: Joo, Hyonsoo, et al.
Publicado: (2021)

Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
por: Ivy, Dunbar, et al.
Publicado: (2021)

Pulmonary artery ablation to treat pulmonary arterial hypertension: a case report
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2015)

Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling
por: Park, Chan Soon, et al.
Publicado: (2022)

Decreased Peak Left Atrial Longitudinal Strain Is Associated with Persistent Pulmonary Hypertension Associated with Left Heart Disease
por: Lee, Ju-Hee, et al.
Publicado: (2022)

Pulmonary Hypertension Secondary to Partial Anomalous Pulmonary Venous Return in an Elderly
por: Koester, Stefan, et al.
Publicado: (2016)

Correction to: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease
por: Joo, Hyonsoo, et al.
Publicado: (2021)

Predictors of residual pulmonary vascular obstruction after anticoagulation monotherapy in patients with intermediate-risk pulmonary embolism
por: Chang, Youjin, et al.
Publicado: (2021)

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience
por: Youssef, David Edward, et al.
Publicado: (2023)

A Case of Extrinsic Compression of the Left Main Coronary Artery Secondary to Pulmonary Artery Dilatation
por: Choi, Yoon-Jung, et al.
Publicado: (2013)

Selective pulmonary artery occlusion to treat hemoptysis associated with pulmonary venous obstruction()
por: Yamauchi, Melissa S.W., et al.
Publicado: (2017)

Pulmonary Arterial Hypertension Secondary to Ethanol Sclerotherapy for Renal Artery Embolization
por: Saba, Raya, et al.
Publicado: (2014)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study
por: Yoo, Su-Jin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_im5lvmvnk5gnj96iestgrt126u